DEFINITION of 'Orphan Drug Credit'

A federal tax credit that provides an incentive for pharmaceutical companies to seek treatments and cures for rare diseases affecting Americans. Normally, companies may not be motivated to make a drug for a small population because sales may be insufficient to justify the research and development costs of creating the drug. The Orphan Drug Credit provides a credit of 50% of clinical drug testing costs for drugs being tested under section 505(i) of the Federal Food, Drug and Cosmetic Act.

BREAKING DOWN 'Orphan Drug Credit'

The credit can be applied whether the clinical tests are performed directly by the pharmaceutical company or are contracted out to a third party. In general, the testing must be conducted within the United States. Orphan drug credits allow pharmaceutical companies to create orphan drugs that target rare conditions.

RELATED TERMS
  1. New Drug Application (NDA)

    The final step formally taken by a drug sponsor, wherein it applies ...
  2. New Indications

    A term used by medical companies and professionals to signify ...
  3. Orange Book

    A list of drugs that the U.S. Food and Drug Administration has ...
  4. Phase 1

    Phase 1 clinical studies or clinical trials are focused on the ...
  5. Side Effect

    Undesirable symptoms caused by taking a drug or undergoing a ...
  6. Medicare Part D

    A prescription drug benefit program that was created through ...
Related Articles
  1. Investing

    Senator Orders Investigation of Orphan Drug Abuse

    Iowa Senator Grassley ordered an inquiry into possible abuse of the Orphan Drug Act by drug makers.
  2. Insights

    How Pharmaceutical Companies Price Their Drugs

    Learn more about how pharmaceutical companies price drugs, why prices are often very high and why it can be difficult to settle on a suitable price.
  3. Investing

    Pharma Balks at German Price Control (BAYRY, RHHBY)

    Drug makers are worried about a proposed new German law that would tighten price controls on prescription drugs.
  4. Investing

    It's No Accident That Drugs Are Expensive

    Branded drugs are expensive in large part because it's expensive and risky to develop them
  5. Insights

    AstraZeneca's NMOSD Drug Gets EU Orphan Drug Status (AZN)

    AstraZeneca's Inebilizumab (MEDI-551) has secured orphan drug status in EU, making it eligible for several key benefits including market exclusivity
  6. Investing

    Opko Gets Orphan Status for Genetic Disorder Drug

    Opko’s neurological disorder drug CUR-1916 qualifies for many benefits under orphan drug status.
  7. Investing

    Drug Prices: Name Brands Doubled in Last 5 Years (ESRX)

    Express Scripts' Drug Trends Report, released Monday, revealed that the average price of brand name drugs rose 16.2% in 2015, with over one third of brand name drugs seeing price increases over ...
  8. Managing Wealth

    6 Common Conditions With Expensive Medications

    While the most expensive drugs may be for rare diseases, there are lots of common conditions that require some pricey prescriptions.
  9. Investing

    Drug Approvals Fell to Six-Year Low in 2016

    New drug approvals dropped to modest levels in 2016 following highs in 2014 and 2015.
  10. Investing

    Drug Giants May Benefit From China Drug Inclusion

    Pharma giants may see higher sales as the Chinese government subsidizes expensive prescription drugs.
RELATED FAQS
  1. How does the profit margin compare for a generic drug versus a brand name drug?

    Learn how the profit margins compare for generic drugs and brand-name drugs. Brand-name drugs cost three to four times more ... Read Answer >>
  2. What are the major barriers to entry for new companies in the drugs sector?

    Find out why barriers to entry for U.S. drug companies are so high and how the Food and Drug Administration, or FDA, inhibits ... Read Answer >>
Hot Definitions
  1. Cryptocurrency

    A digital or virtual currency that uses cryptography for security. A cryptocurrency is difficult to counterfeit because of ...
  2. Financial Industry Regulatory Authority - FINRA

    A regulatory body created after the merger of the National Association of Securities Dealers and the New York Stock Exchange's ...
  3. Initial Public Offering - IPO

    The first sale of stock by a private company to the public. IPOs are often issued by companies seeking the capital to expand ...
  4. Cost of Goods Sold - COGS

    Cost of goods sold (COGS) is the direct costs attributable to the production of the goods sold in a company.
  5. Profit and Loss Statement (P&L)

    A financial statement that summarizes the revenues, costs and expenses incurred during a specified period of time, usually ...
  6. Monte Carlo Simulation

    Monte Carlo simulations are used to model the probability of different outcomes in a process that cannot easily be predicted ...
Trading Center